Skip to main content

Table 5 Overall survival related to clinicopathological features and biomarkers. 182 patients with breast cancer were included and the differences between these OS Rates were tested using the Kaplan–Meier method with log rank test

From: Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study

Variables

Patients

Events

OS rate (%)

P

3-year (95 % CI)

5-year (95 % CI)

(log-rank)

Age, year

     

  ≤ 60

153

45

78.3 (71.6, 85.0)

68.5 (60.1, 76.9)

0.074

  > 60

29

13

62.0 (43.2, 80.8)

62.0 (43.2, 80.8)

 

Depth of invasion

     

 T0 ~ T2

108

22

83.1 (75.7, 90.5)

78.0 (69.2, 86.8)

<0.001

 T3 ~ T4

72

35

66.3 (55.3, 77.3)

54.3 (41.8, 66.8)

 

Lymph node metastasis

     

 N0 ~ N1

93

17

87.8 (81.1, 94.5)

84.2 (76.2, 92.2)

<0.001

 N2 ~ N3

87

40

63.3 (52.7, 73.9)

49.3 (37.0, 61.6)

 

TNM stage

     

 I ~ II

74

9

92.9 (87.0, 98.8)

88.2 (79.8, 96.6)

 

 III ~ IV

107

49

63.6 (54.2, 73.0)

52.7 (41.9, 63.5)

<0.001

ER

     

 Negative

69

25

68.1 (56.7, 79.5)

63.6 (51.4, 75.8)

0.242

 Positive

110

31

80.9 (73.5, 88.3)

69.3 (59.1, 79.5)

 

PR

     

 Negative

107

39

65.8 (56.6, 75.0)

62.7 (52.9, 72.5)

0.036

 Positive

72

17

91.3 (84.6, 98.0)

73.7 (60.8, 86.6)

 

HER2

     

 Negative

108

27

80.9 (73.5, 88.3)

75.3 (65.9, 84.7)

0.028

 Positive

70

29

71.1 (60.1, 82.1)

56.2 (43.5, 68.9)

 

C1orf63

     

 Negative

138

50

73.5 (65.9, 81.1)

64.9 (56.1, 73.7)

0.145

 Positive

44

8

83.3 (71.9. 94.7)

76.9 (61.0, 92.8)3

Â